GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (STU:IF0) » Definitions » Deferred Tax

InflaRx NV (STU:IF0) Deferred Tax : €0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

InflaRx NV's change in deferred tax for the three months ended in Sep. 2024 was €0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil.

InflaRx NV Deferred Tax Historical Data

The historical data trend for InflaRx NV's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Deferred Tax Chart

InflaRx NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Deferred Tax
Get a 7-Day Free Trial Premium Member Only - - - - -

InflaRx NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

InflaRx NV Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InflaRx NV Deferred Tax Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

InflaRx NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (STU:IF0) » Definitions » Deferred Tax
Comparable Companies
VXRT INO NKTX THRX ANIX CDXC PRLD AADI PRQR MLEC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
IFRX:USA
Address
Winzerlaer Strasse 2, Jena, DEU, 07745
Website
https://www.inflarx.de
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

InflaRx NV Headlines

No Headlines